Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Ovarian cancer classification system validated
Fri January 15th - A newly developed method for subtyping ovarian cancer has been validated as accurately predicting disease outcome. More
How euthanasia rates vary across The Netherlands
Fri January 15th - Regions of The Netherlands have recorded a seven-fold unexplained variation in euthanasia rates, according to new analysis published today. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 04/08/2020 VICKY P ADAM wrote:
I would like to thank WORLD HERBS CLINIC for reve... on Medieval remedy for bacterial ...
On 29/07/2020 Amdre wrote:
When i read many blogs online about cure to HSV, a... on Medieval remedy for bacterial ...
On 14/07/2020 margret wrote:
I was diagnosed of ALS (amyotrophic lateral sclero... on Heart abnormalities revealed i...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...

Urine test hope to detect prostate cancer

Monday October 18th, 2010

A new urine test could be used to identify men who are at risk of prostate cancer, researchers say.

Scientists from Cancer Research UK have found that changes to a protein, which regulates prostate cell death, is linked to an increased risk of developing prostate cancer.

Their research, published in PLoS ONE, suggests that levels of the microseminoprotein-beta protein in urine could form the basis for a new test that will enable men to ascertain if they are at greater risk of developing the disease.

It could also be used alongside the prostate specific antigen blood test to improve detection of prostate cancer and for monitoring progression of the disease.

Lead study author, Dr Hayley Whitaker, from Cancer Research UK’s Cambridge Research Institute, said they were excited by the discovery, which was made after examining tissue and urine of more than 350 men, some of whom had already been diagnosed with the disease.

“The protein is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk of developing the disease,” she said.

Study author Professor Rosalind Eeles, from the ICR and The Royal Marsden Hospital, London, added: “At the moment, PSA testing is the best method we have to detect prostate cancer but it has significant limitations, so there is an urgent need to find new biomarkers such as MSMB that could be used in screening and diagnosis.”

Prostate cancer is the most common cancer in men in the UK. In 2006, more than 35,000 men in the UK were diagnosed with the disease. Each year about 10,200 men in the UK die from it.

Professor David Neal, prostate cancer specialist at Cancer Research UK’s Cambridge Research Institute, said: “This is a vital piece of research that could go a long way to find a long-awaited and much-needed reliable and easy test to identify those men most at risk of developing prostate cancer.

If further studies show this marker can be used in the clinic this will be a landmark discovery.”

The rs 10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotien-beta expression in tissue and urine. PLoS ONE October 13 2010

Tags: Cancer | Menís Health | UK News

Printer friendly page Printer friendly page